Оптимизация методов коррекции нарушений нормоценоза влагалища при первичном обращении пациенток

Abstract

Objective. To study the efficacy and feasibility of using dequalinium chloride during the primary treatment of patients of reproductive age with the symptoms of disorders of vaginal normocenosis. Patients and methods. In 60 patients of reproductive age (31.43 ± 6.44 years), an observational study was conducted, in which the initial data characterizing the state of vaginal microbiota were evaluated, and also the dynamics of their change immediately after treatment and after one month were presented. The analysis of risk factors for vaginal normocenosis disorders and dynamics of changes in the clinical picture amid dequalinium chloride therapy (Fluomizin®) was performed. Results. Significant risk factors for disorders of vaginal normocenosis are: early sexual activity (28.3%), the number of sexual partners (4.32 ± 4.11), their frequent change (13.33%), which determine hormonal and immune changes in the mucosa against the background of endocrine pathology (hypothyroidism in 8.33%) and genital endometriosis (in 35.0%). The prescription of Fluomizin® led to the relief of symptoms (itching, burning, discomfort, discharge and hyperemia) after 6 days of its use, which is confirmed by the data of the study (vaginal swabs, Femoflor 16). Conclusion. Dequalinium chloride (Fluomizin®) can be used to correct the disorders of vaginal normocenosis in the initial treatment of patients before obtaining the results of laboratory studies. Key words: reproductive period, vaginal health, dequalinium chloride, treatment quality